Principle of Thailand Medicine Reclassification Guidelines

Mrs. Nantarat Sukrod Bureau of Drug Control Food and Drug Administration

September 17, 2015



Content

- Drug classifications of Thailand
- Decision in Drug reclassification
- Worldwide Drug reclassification guideline
 - WHO guideline
 - European Directive
 - UK MHRA guideline
- Common Practice in Reclassification
- (Draft) Thailand Reclassification guideline



Drug classifications of Thailand



Characteristics of drug classifications in Thailand



Decision in Drug reclassification



Decision factors in drug reclassification



GSL	General Sale List medicine
Р	Pharmacy medicine
POM	Prescription-only medicine (Rx)



Worldwide Drug reclassification guideline

- WHO guideline
- European Directive
- UK MHRA guideline



Comparative Drug Classification (vs Thailand)

WHO	Rx (prescription)	OTC (non-prescrip	tion)
EU	Rx (prescription)	OTC (non-prescrip	otion)
UK	Rx (prescription)	Pharmacy	GSL
Thailand	Rx (prescription)	Pharmacy (non-Ads) Dangerous drug	GSL



WHO's OTC reclassification guideline

WHO

Rx (prescription)

OTC (non-prescription)

WHO/EDM/QSM/00.1 Original: English Distribution: General

Guidelines for the Regulatory Assessment of Medicinal Products for use in Self-Medication

> World Health Organization Geneva 2000

Basic Criteria for a self-medication product.

(1) The active ingredient at the intended dose should have low inherent toxicity.

(2) The intended use should be appropriate for self-medication.

(3) The product should not have properties that make it undesirable.



WHO's OTC reclassification guideline

WHO

Rx (prescription)

OTC (non-prescription)

WHO/EDM/QSM/00.1 Original: English Distribution: General

Guidelines for the Regulatory Assessment of Medicinal Products for use in Self-Medication

> World Health Organization Geneva 2000

Additional Criteria.

(1) The use of the product has been sufficiently extensive or in high enough volume.

(2) The product has been marketed on prescription for at least five years.

(3) Its adverse events give no cause for concern, and their frequency has not increased unduly during the marketing period.



EU

Rx (prescription) OTC (non-prescription)



Guideline of Rx-to-OTC switch

(1) Medicinal products should not present a danger either directly or indirectly, even when used correctly, if utilized without medical supervision.

DIRECT DANGER

- low general toxicity and no relevant reproductive toxicity, genotoxic or carcinogenic properties
- low risk of serious type A adverse reactions and very low risk of serious type B reactions in the general population
 - Note: The criterion of danger can take account of the possibility of preventive action. For example, serious type A reactions can be acceptable if there is a clear identifiable risk group that can be excluded even in the absence of medical supervision.



teuropean commission texterrise and industry directorate-general. texterrise and industry directorate-general.
Revision January 2006
A GUIDELINE ON CHANGING THE CLASSIFICATION FOR THE SUPPLY OF A MEDICINAL PRODUCT FOR HUMAN USE This guideline will be included in The Rules governing Medicinal Products in the European Community Volume 2C: Guidelines
Rue de la Loi 200, B-1049 Bruxelles/Wetstraat 200, B-1049 Brussel - Beiglum - Office: RP 11 4/57. 1 Telephone: direct line (+32-2)2591529, exchange 299.11.11. Fax: 2961520. Telex: COMEU B 21877. Telegraphic address: COMEUR Brussels.

Guideline of Rx-to-OTC switch (cont)

INDIRECT DANGER

- Use of the medicine should not delay diagnosis and definitive treatment and jeopardise the chance of more successful therapy.
 - Note: Package leaflet and or label warnings may be necessary to prevent treatment from "masking" the development of a serious disorder.
- Wider use of the medicine should not increase the risk of resistance to the product, or if the symptom is found in diverse range of underlying pathologies, or where the patient cannot easily discern the underlying disease.



	EUROPEAN COMMISSIO ENTERRISE AND INDUSTRY DIREC Consumer goods Pharmaceuticass	
	CUIDELINE ON	Revision January 2006
CLASS	SIFICATION FO	R THE SUPPLY OF A T FOR HUMAN USE
This guid	eline will be included in The I in the European Communit	Rules governing Medicinal Products y Volume 2C: Guidelines
Rue de la Loi 200, 8-1 Telephone: direct line : Telephone: direct line :	049 Bruxelies/Wetstraat 200, B-1049 Brus 132-212551529, exchange 299.11.11.F aa 7. Telegraphic address. COMEUR Brusce	sel - Belgium - Office: RP 11 4/57. 1 2961520.

Guideline of Rx-to-OTC switch (cont)

SELF-ASSESSMENT CONDITIONS/SYMPTOMS

- Able to assess the disease, the condition, the duration of symptoms and their reoccurrence and consequences
- Able to exclude similar conditions which is not unsuitable for such medicine treatment
- Able to understand contraindications, interactions, warnings and precautions
 - Note: availability of appropriate information sources that would assist the patient in achieving this, including written information or the advice of pharmacist and other health care professionals.

INCORRECT USE

 low risk & consequences, when it is misused (off-label use, longer use, overdose)



ÉUROPEAN COMMISSION Setemprise and industry directorate-general Setemprise and industry directorate-general Consumer goods Pharmaceuticals
Revision January 2006
A GUIDELINE ON CHANGING THE CLASSIFICATION FOR THE SUPPLY OF A MEDICINAL PRODUCT FOR HUMAN USE This guideline will be included in The Rules governing Medicinal Products in the European Community Volume 2C: Guidelines
Rue de la Loi 200, B-1049 Bruxelles/Weistraat 200, B-1049 Brussel - Beigium - Office: RP 11 4/57. 1 Telephone: direct line (+32-2)2951539, exchange 299.11.11. Fax: 2961530. Telex: COMEU B 2177. Telegraphic address: COMEUB Brussels.

Guideline of Rx-to-OTC switch (cont)

- (2) Medicinal products shall not frequently and to a very wide extent be used incorrectly, and as a result are likely to present a direct or indirect danger to human health.
- (3) Medicinal products shall not contain substances or preparations thereof the activity and/or side-effects of which require further investigation, for example:-
- Recent authorization/limited experience
- New strength, dose, route of administration, indication, new age group or combination of substances.

(4) Medicinal products shall not be administered parenterally (for injection)



UK MHRA guideline #11: Changing the legal classification in the UK of a medicine for human use

UK

Rx (prescription) Pharmacy GSL

Back 🔹 💭 👘	🖹 🗿 🟠	🔎 Search 🔶 Fav	vorites 🚱 🎸	3 · 🍇 🗹 · 🚺	🛛 🖹 🎁 🖓 🔛					
ss 🗃 http://www.		eregulate/Medicines/Licens							🗸 🏓 Bo	Li
ος 💽 πτφ.//www.	a.gov.ukjnow	ereguiste/neutries/uteri	singoimearanespeej	yastatusai ti etiassi itatu						
HRA					Home	Pharmaceutical industry	Contact us FAQs Glos	isary Sitemap	A-Z index Access keys	He
								Site Se	earch	Go
									Advanced s	searc
bout us	How we regula	e Safety	information	Committees	Conferences & Learning Centre	Online services	Publications	News Cr	entre Your vier	WS
				_				-		-
icensing of dicines	Hor	ne > How we regulate > M	ledicines > Licensir	ng of medicines > Legal s	tatus and reclassification					
Jicines	L	egal status a	and recla	esification						
inical trials	-	igai statas t		Joincation						
indui sinara	Th	a postion dotails the	local status or	nd the real and fraction	in procedures for medici	non including lists of sub	stances for properint	ion only	Printer friendly version	n
						nes including lists of sub 1 since April 2002	stances for prescrip	tion only,	Printer friendly version (new window)	n
larketing authorisati	ph				n procedures for medici d substances reclassified		stances for prescript	tion only,		n
larketing authorisati Iarallel import licence	ph						stances for prescript	tion only,		
arketing authorisati arallel import licence anufacturer's and 1	ouns ph ces Wholesale						stances for prescript	tion only,	(new window) Related information MHRA pages:	
arketing authorisati arallel import licence anufacturer's and 1	ph ces Wholesale	armacy and general n this section	sale supply an				stances for prescripi	iion only,	(new window) Related information MHRA pages: > ARMs: Applications to	
arketing authorisati arailel import licence anufacturer's and 1 ealer's licences egal status and	ph ces Wholesale	armacy and general In this section Legal status of medic	sale supply an				stances for prescripi	tion only,	(new window) Related information MHRA pages: > ARMs: Applications to reclassify medicines > Availability of medicines	1:
larketing authorisati	buils ph ces Wholesale	armacy and general In this section Legal status of medic Reclassification: the c	sale supply an				stances for prescript	tion only,	(new window) Related information MHRA pages: ARIIs: Applications to reclassify medicines Availability of medicines Commission on Human	1:
arketing authorisati analiel import licence anufacturer's and 1 ealer's licences egal status and eclassification	ces ph Wholesale I	armacy and general n this section Legal status of medic Reclassification: the c Reclassification proce	sale supply an cines criteria edures	id a list of authorised			stances for prescript	tion only,	(new window) Related information MHRA pages: > ARUs: Apploations to reclassify medicines > Availability of medicines > Commission on Human Medicines	1:
larketing authorisati arallel import licence lanufacturer's and 1 ealer's licences egal status and eclassification Lists of substance	ces ph Wholesale I es ,	armacy and general In this section Legal status of medic Reclassification: the c	sale supply an cines criteria edures i policy subseque	id a list of authorised			stances for prescript	ion only,	(new window) Related information MHRA pages: ARIIs: Applications to reclassify medicines Availability of medicines Commission on Human	1:
artieting authorisati araitel import licenci- anufacturer's and facturer's and acaler's licences egal status and cclassification Lists of substance Recent reclassifica	bails ph ces Wholesale	armacy and general In this section Legal status of medic Reclassification the of Reclassification proce Changes in licensing implementation of the Supplementary inform	sale supply an criteria edures policy subseque new reclassifica nation	id a list of authorised			stances for prescript	ion only,	(new window) Related information MHRA pages: > ARIA Applications to reclassify medicines > Commission on Human Medicines Other sites: (open in a new window) > Extrafleck Volume 2 -	1: (
larketing authorisati arallel import licence lanufacturer's and 1 ealer's licences egal status and	bails ph ces Wholesale	armacy and general n this section Legal status of medic Reclassification the o Reclassification proce Changes in licensing implementation of the	sale supply an criteria edures policy subseque new reclassifica nation	id a list of authorised			stances for prescript	lion only,	(new window) Related information MHRA pages: > ARMs: Applications to reclassify medicines > Availability of medicines > Commission on Human Medicines Other sites: (open in a new window	1: (
arketing authorisati anufacturer's and i anufacturer's and i acaler's licences egal status and eclassification Lists of substance Recent reclassifica	bails ph ces Wholesale	armacy and general In this section Legal status of medic Reclassification the of Reclassification proce Changes in licensing implementation of the Supplementary inform	sale supply an dines criteria edures i policy subseque i new reclassifica nation	id a list of authorised			stances for prescript	lion only,	(new window) Related information MHRA pages: ARIIs: Applications to reclassly medicine A valiability of medicines Cother sities: (open in a new window) Petorte.ex.oure 2 - Pharmaceutical Legistic Notice to Applications The Itedicines for Huma	n: ; v) tion
arieting authorisati aralel import licence anufacturer's and asier's licences egal status and classification Lists of substance Recent reclassificz etter Regulation of thative (BROIII) consing time-basec	ph ces Wholesale	armacy and general n this section Legal status of medic Reclassification the c Reclassification proce Changes in licensing implementation of the Supplementary inform Contact for further info	sale supply an ines criteria edures policy subseque new reclassifica nation parmation	id a list of authorised			stances for prescript	ion only,	(new window) Related information MHRA pages: AMI% Appletions to reclassify medicines A Availability of medicines Commission on Human Medicines Other sites: (open in a new window) Extract.ex Could Calponsts The lifedicines for Huma Use and Idecia Delations The lifedicines for Huma The lifedicines	n: v) tion an es us
arieting authorisati aralel import licence anufacturer's and asier's licences egal status and classification Lists of substance Recent reclassificz etter Regulation of thative (BROIII) consing time-basec	es photosale pho	armacy and general this section Legal status of medic Reclassification proc Changes in Lensing implementation of the Supplementary inform Contact for further info gal status of medic	sale supply an sines criteria edures i policy subseque reveredassifica antion mination	int to	substances reclassified				(new window) Related information MIRA pages: AMIts Applications to reclassly methicines A valiability of mechanissly methicines Coher sin a new window Copen in a new window Copen in a new window Planmaceutical Lepals Notice to Applications The Electorises frituation Was and Informational Lepals Notice to Applications The Electorises frituation The Information of the Communication The Information of the Communication (information of the Communication) The Information (information of the Communication) The Inform	n: ; tion: an es JS
artieting authorisati arailel import licenci anufacturer's and f anufacturer's and f anufacturer's and f easier's licences egal status and cclassification Lists of substance Recent reclassification etter Regulation of tabative (BROM) icensing time-basec erformance measure ess for medicines,	es photosale pho	armacy and general armacy and general this section Legal status of medic Reclassification proc Contact for further info Contact for further info gal status of medic publicates Art 1988 ar 1980 arms and 1980 ar Status of the section of the Status of the section of the section of the section of the Status of the section of the section of the section of the Status of the section of the section of the section of the Status of the section o	sale supply an ines criteria edures policy subseque a new reclassifica nation primation dicines di Council Directi (A) and products	ent to the smaller of authorised entry of the smaller of the small	j substances reclassified (the sale and supply of me on a prescription (prescrip	i since April 2002.	nedicinal products is pa or available in a pharm	it of the	(new window) Related information MHRA pages: AMIs: Applications to reolsast/medicines AMIs: Applications to reolsast/medicines Coher sites: (open in a new window > Eudrate: Volume 2- Pharmaceutical Lepistit Notice to Applicants > The flections of Huma Water of the applicants > The flections of Huma Water of the applicants > The flections of Huma Medicines Amendmeths Pharmaceutical Reputat	n: ; tion: an es JS
arketing authorisati arailel import licenco anufacturer's and i ealer's licences egal status and actas sification Lists of substance etter Regulation of faative (BROM) consing time-base erformance measure	kins ph ses ph wholesale l ses ph set ph ses ph set ph s	armacy and general armacy and general this section Legal status of medic Reclassification the ce Reclassification the ce Reclassification the ce Reclassification the ce Reclassification the ce Supplementary inform Contact for further info Contact for further info Reclassification the ce status of medic lifediones that 1986 ar the fielding school to field the fielding school to	sale supply an criteria edures policy subseque new reclassifica nation ormation dicines di Council Direct (A) and products the superision	et to authorised	J substances reclassified if the sale and supply of me on a prescription (prescrip on a prescription	i since April 2002.	nedicinal products is particular to a pharm	it of the tacy	(new window) Related information MHRA pages: AMIs: Applications to reolsast/medicines AMIs: Applications to reolsast/medicines Coher sites: (open in a new window > Eudrate: Volume 2- Pharmaceutical Lepistit Notice to Applicants > The flections of Huma Water of the applicants > The flections of Huma Water of the applicants > The flections of Huma Medicines Amendmeths Pharmaceutical Reputat	v) tion: an es us ons

Guideline of POM-to-P switch

- 1) should not have a direct or indirect danger exists to human health, even when used correctly, if used without medical supervision; or
- 2) there is no frequently incorrect use which could lead to direct or indirect danger to human health; or
- 3) further investigation of activity and/or side-effects is not required; or
- 4) not to be administered parenterally.
- *Note: this is same as EU guideline on changing the classification of the supply of a medicinal product for human use (2006) 2001/83/EC*



UK MHRA guideline #11: Changing the legal classification in the UK of a medicine for human use

UK

Rx (prescription)



- B X Legal status and reclassification : MHRA - Microsoft Internet Explore File Edit View Favorites Tools Help . 🔇 Back 🔹 🕗 🐇 😰 🟠 🔎 Search 👷 Favorites 🚱 🔗 🍓 🔟 🔹 🧾 🎼 鑬 🦓 iddress 🗃 http://www.mhra.gov.uk/Howweregulate/Medicines/Licensingofmedicines/Legalstatusandreclassification/index.htm 🗸 🔁 Go Links Home Pharmaceutical industry Contact us FAQs Glossary Sitemap A-Z index Access keys Help MHRA Go Site Search Advanced searc Conferences & About us How we regulate Safety information Publications News Centre Your views Learning Centre In Licensing of Home > How we regulate > Medicines > Licensing of medicines > Legal status and reclassification medicines Legal status and reclassification **Clinical trials** Printer friendly version This section details the legal status and the reclassification procedures for medicines including lists of substances for prescription only Marketing authorisation (new window pharmacy and general sale supply and a list of authorised substances reclassified since April 2002 Parallel import licences **Related** information Manufacturer's and Wholesal MHRA pages: In this section ... Dealer's licences > ARMs: Applications to reclassify medicines Legal status of medicines Legal status and > Availability of medicine reclassification Reclassification: the criteria > Commission on Human Reclassification procedures Medicines > Lists of substances Changes in licensing policy subsequent to Other sites: implementation of the new reclassification (open in a new window) > Recent reclassifications Supplementary information » Fudral ex: Volume 2 -Pharmaceutical Leoislatio Better Regulation of Medicines Contact for further information Notice to Applicants Initiative (BROMI) » The Medicines for Human Use and Medical Devices Licensing time-base (Fees and Miscellaneous Legal status of medicines performance measures Amendments) Regulations The Medicines Act 1968 and Council Directive 2001/83/EEC control the sale and supply of medicines. The legal status of medicinal products is part of the 2002 - SI 2002/542 Fees for medicines blood marketing authorisation (MA) and products may be available either on a prescription (prescription only medicines (POMs)), or available in a pharmacy establishments and blood banks without prescription, under the supervision of a pharmacist (P) or on general sale (GSL). Prescriptions can be issued by doctors, dentists, nurse independent prescribers, pharmacist independent prescribers and supplementary prescribers. For further information, please see the section below Featured publications: Information for licence holders Internet Done 🛃 Adobe Reader 🖉 (Ref) Changing... 🖉 gn 11[1] - Micro... 🛛 EN 🔇 🖸 🌚 1:38 AM 🛃 start 🔰 🙆 🥭 💽 🏅 2 Microsoft Of... 🔹 🏙 Review of OTC 📋 Reference

Guideline of P-to-GSL switch

- 1) hazard to health and risk of misuse is small and that significant special precautions in handling are not required.
- 2) must not be categorized in group of Anthelmintics, Parenterals, Eye drops, Eye ointments, Enemas, Irrigations used for wounds, bladder, vagina or rectum, Aspirin or Aloxiprin for administration to children

3) No need to get professional advice at the time of purchase.



GSL

Common Practice in Reclassification



Common Practice in Reclassification





Draft Thailand Reclassification guideline



General factors to be considered in reclassification





Drug Classification



THAILAND

Specially Controlled Drug



Drug which classified as Specially Controlled Drug

1. Chance of incidence of **danger caused directly by drug**, even if used correctly without supervision by physician because drug has:

	Antineoplasitics e.g. Paclitaxel	Antivirals e.g. Zidovudine
1.1 High General toxicity	\checkmark	\checkmark
1.2 Reproductive Toxicity, Genotoxicity ,Mutagenicity	Clastogenic (in vitro, in vivo)	Mutagenic in 5178Y/TK+/- mouse lymphoma assay
1.3 Serious ADR type A frequency : Very Common - Common	Anemia	Bone marrow depression
1.4 Serious ADR type B frequency : Very Common - Rare	Polyneuropathy	Immune reconstitution syndrome. Autoimmune disorders
1.5 Serious Drug-Drug interaction or Drug-Food interaction	Drug interaction with enzyme inhibitors e.g. ketoconazole and other imidazole antifungals, erythromycin, fluoxetine, gemfibrozil, cimetidine or enzyme inducers e.g.rifampicin, carbamazepine, phenytoin, efavirenz,	Drug interaction to Antiretroviral Agents , Doxorubicin, Phenytoin, ganciclovir
	and nevirapine) involving CYP2C8 and CYP3A4.	FOOD AND DRUG ADMINISTRATION

Drug which classified as Specially Controlled Drug (Con't)

2. Possibly cause serious **indirect harm** from the treatment which masks actual symptoms requiring medical care e.g. cancers <u>or</u> heart diseases, despite of correct usage without physician supervision.

Example: Oral corticosteroid e.g. Prednisolone, Cortisone.



Drug which classified as Specially Controlled Drug (Con't)

3. Its use requires physician supervision or it has frequent incorrect use

Example: Steroid containing products for inhalation



Drug which classified as Specially Controlled Drug (con't)

4. Indication purposed for the treatment of symptoms <u>or</u> diseases of which cannot diagnosed by the patient him/herself.

Example: Antipsychotic drugs General Anaesthetic



Drug which classified as Specially Controlled Drug (con't)

5. Highly negative impacts to society even though there is evidence to support the safety and can be classified as dangerous drug such as

Narcotic drugs <u>or</u>

Psychotropic drugs or

A drug led to addiction when abuse or

A drug used by unintended purpose to violate laws, etc.

Example: Misoprostol



Dangerous Drug



Drug which classified as **Dangerous Drug**

1. No characteristics of specially controlled drug

2. Administration <u>not</u> required under physician supervision. Pharmacist can give proper and safe instructions to patients.

Example: Antiviral drugs for external use



Drug which is not Dangerous or Specially Controlled Drug (non-Dangerous Drug)



Drug which not classified as Dangerous or Specially Controlled Drug

1. No characteristics of Dangerous Drug and Specially Controlled Drug.

2. Not an injectable dosage form.



Drug which not classified as Dangerous Drug and Specially Controlled Drug(con't)

3. Low risk with well supportive data in patients require specialized care such as elderly, pregnant women, lactating women and patients with hepatic and renal impairment.

Example: Muselytic

Acetylcysteine	
Effervescent tablet, Granule	
Used to dissolve mucus and to facilitate expectoration during respiratory diseases	
В	
Not required	
No toxic concern	

Drug which not classified as Dangerous Drug and Specially Controlled Drug(con't)

4. Administration <u>not</u> required an instruction from physicians or pharmacists ; easy to use when following the instructions on a label or package insert.

Example : Mouthwash



Household Remedy Drug



Household Remedy Drug (Self-care, GSL)

- 1. No characteristics specified under the category of Specially Controlled Drugs or Dangerous drugs
- 2. Not formulated as injection form
- 3. Indication for treatment of disease or symptom which can be self-diagnosed
- 4. Administration is not complicated in User Instructions of product insert
- Low risk with well supportive data in patients require specialized care such as Elderly, Pregnant women, Lactation women, and patient with liver and renal impairment



Household Remedy Drug (Self-care, GSL)

Example: <u>Carbon for Anti-diarrhea</u> Activated charcoal 250-350 mg

Indication: Treatment of diarrhea



Drug Reclassification Status

- Status :
 - Drug Reclassification Application Guideline
 - Public hearing : 24 September 2014



- Drug Reclassification Guideline
 - Public hearing : 7 July 2015
- Announcement : Target in November 2015



Three Years Roadmap





FOOD AND DRUG ADMINISTRATION

Thank you ขอบคุณค่ะ

